(Q35609730)

9 August 2017

1 reference

title

Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy (English)

1 reference

9 August 2017

main subject

anti-retroviral agent

0 references

1 reference

1

Pedro Cahn

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Expert Opinion on Investigational Drugs

9 August 2017

published in

1 reference

9 August 2017

volume

13

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

55-68

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Time to act: global apathy towards HIV/AIDS is a crime against humanity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Once‐a‐Day Highly Active Antiretroviral Therapy: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Assessment of the relative potency of emtricitabine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

A comparison study of multiple measures of adherence to HIV protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Expanding directly observed therapy: tuberculosis to human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

New developments in anti-HIV chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

Directly observed therapy and treatment adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.55

21 January 2018

Identifiers

DOI

10.1517/13543784.13.1.55

1 reference

9 August 2017

1 reference